A NEW DRUG FOR PATIENTS WITH GLIOBLASTOMA
A NEW DRUG FOR PATIENTS WITH GLIOBLASTOMA A new investigational drug, Rhenium Obisbemeda (186RNL), developed at UT Health San Antonio, has shown remarkable potential to extend survival for patients with glioblastoma, the most common and aggressive primary brain tumor in adults. In a phase 1 clinical trial, the therapy more than doubled median survival and […]